Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2b/3 Data of Oral ANAVEX®2-73 (blarcamesine) for Early Alzheimer’s Disease at the Upcoming Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022
October 17 2022 - 7:00AM
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:
AVXL), a clinical-stage biopharmaceutical company developing
differentiated therapeutics for the treatment of neurodegenerative
and neurodevelopmental disorders including Alzheimer’s disease,
Parkinson’s disease, Rett syndrome and other central nervous system
(CNS) disorders, today announced that the company will present
Phase 2b/3 ANAVEX®2-73-AD-004 data of oral ANAVEX®2-73
(blarcamesine) for Early Alzheimer’s Disease at the upcoming
Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022 in San
Francisco, CA and publish the findings in a peer-reviewed medical
journal.
Top Line Data of ANAVEX®2-73 (blarcamesine) Randomized,
Double-blind, Multicenter, Placebo-controlled Phase 2b/3 in
Patients with Early Alzheimer’s Disease (AD)Date / Time:
December 1, 2022 / 4:30pm PTPresenter: A/Prof. Stephen Macfarlane,
Principal InvestigatorSession Title: LB8 - LATE BREAKING ORAL
COMMUNICATIONS
ANAVEX®2-73 (blarcamesine) is an orally
available, small-molecule activator of the sigma-1 receptor
(SIGMAR1), which, data suggest, is pivotal to restoring neural cell
homeostasis and promoting neuroplasticity.1
Prior to the completion of the larger Phase 2b/3
study ANAVEX®2-73-AD-004 (NCT03790709) for the treatment of Early
Alzheimer’s Disease, using precision medicine included SIGMAR1
biomarker of response, ANAVEX®2-73 (blarcamesine) successfully
completed a randomized, double-blind, multicenter,
placebo-controlled Phase 2 in Parkinson’s disease dementia and a
Phase 2a clinical trial for Alzheimer’s disease. In addition,
ANAVEX®2-73 (blarcamesine) successfully completed a randomized,
double-blind, multicenter, placebo-controlled Phase 2 in adult Rett
syndrome and a randomized, double-blind, multicenter,
placebo-controlled Phase 3 in adult Rett syndrome,
respectively.
Economic Burden of Alzheimer's Disease2
Alzheimer's disease is the most common cause of
dementia and the fifth leading cause of death in adults older than
65 years. The estimated total healthcare costs for the treatment of
Alzheimer's disease in 2020 were estimated at $305 billion, with
the cost expected to increase to more than $1 trillion as the
population ages. Most of the direct costs of care for Alzheimer's
disease are attributed to skilled nursing care, home healthcare,
and hospice care. Indirect costs of care, including quality of life
and informal caregiving, are likely underestimated, and are
associated with significant negative societal and personal
burdens.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of novel therapeutics for the treatment of
neurodegenerative and neurodevelopmental disorders, including
Alzheimer's disease, Parkinson's disease, Rett syndrome, and other
central nervous system (CNS) diseases, pain, and various types of
cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine),
has successfully completed a Phase 2a clinical trial for
Alzheimer's disease, a Phase 2 proof-of-concept study in
Parkinson's disease dementia, and both a Phase 2 and a Phase 3
study in adult patients with Rett syndrome. ANAVEX®2-73 is an
orally available drug candidate that restores cellular homeostasis
by targeting sigma-1 and muscarinic receptors. Preclinical studies
demonstrated its potential to halt and/or reverse the course of
Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant,
anti-amnesic, neuroprotective, and anti-depressant properties in
animal models, indicating its potential to treat additional CNS
disorders, including epilepsy. The Michael J. Fox Foundation for
Parkinson's Research previously awarded Anavex a research grant,
which fully funded a preclinical study to develop ANAVEX®2-73 for
the treatment of Parkinson's disease. ANAVEX®3-71, which targets
sigma-1 and M1 muscarinic receptors, is a promising clinical stage
drug candidate demonstrating disease-modifying activity against the
major hallmarks of Alzheimer's disease in transgenic (3xTg-AD)
mice, including cognitive deficits, amyloid, and tau pathologies.
In preclinical trials, ANAVEX®3-71 has shown beneficial effects on
mitochondrial dysfunction and neuroinflammation. Further
information is available at www.anavex.com. You can also connect
with the company on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
For Further Information:Anavex
Life Sciences Corp.Research & Business DevelopmentToll-free:
1-844-689-3939Email: info@anavex.com
Investors:Andrew J.
BarwickiInvestor RelationsTel: 516-662-9461Email:
andrew@barwicki.com
1 Advances in Experimental Medicine and Biology Volume 964
(2017) Sigma Receptors: Their Role in Disease and as Therapeutic
Targets.2 W Wong Economic Burden of Alzheimer Disease and Managed
Care Considerations Am J Manag Care. 2020;26:S177-S183.
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Jul 2024 to Aug 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Aug 2023 to Aug 2024